Marketwire - Pharmaceuticals and Biotech

Pharmaceutical-Biotech Industry Investment Update: $5.6 Billion in Capital/Maintenance Began Construction in 3Q09, an Industrial Info News Alert

Mon, 23 Nov 2009 05:15:00 EST

SUGAR LAND, TX--(Marketwire - November 23, 2009) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The Pharmaceutical-Biotech Industry is weathering the current economic storm well, sailing through the third quarter of 2009 with $5.6 billion in construction starts. A recent survey of active reported capital and maintenance projects in Industrial Info's Pharmaceutical Tracker - Online Database revealed that the total investment value of the projects is spread over 185 separate projects, resulting in an average project investment of $30 million.

Eminent Canadian Diabetes Scientist Joins Sirona Biochem's Scientific Advisory Board

Mon, 23 Nov 2009 05:00:00 EST

VANCOUVER, BC--(Marketwire - November 23, 2009) - Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on drug development for diabetes and obesity, announced today another major appointment to its Scientific Advisory Board, Professor Bruce Verchere, one of Canada's leading diabetes scientists.

Sirona Biochem CEO, Dr. Howard Verrico, said, "We consider ourselves very fortunate indeed to have attracted Professor Verchere to participate on the Scientific Advisory Board. He is one of the leading researchers in the global battle against diabetes which has become a true epidemic that unfortunately is now affecting the young, a particular focus for him.

Agennix AG Reports Financial Results for Third Quarter and First Nine Months of 2009

Mon, 23 Nov 2009 02:48:00 EST

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - November 23, 2009) -

Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced financial results for the third quarter and first nine months ended September 30, 2009.

Agennix AG was formed by the combination of GPC Biotech AG and Agennix Incorporated. The accounting for the business combination will be based on the acquisition method specified in IFRS 3, Business combinations (revised 2008). Based on that accounting treatment, GPC Biotech AG has been identified as the acquirer and Agennix Incorporated as the acquiree in this transaction. Therefore, the historical financial information of Agennix AG, including the information presented below, is that of GPC Biotech AG. Furthermore, for future financial reports, the comparative historical financial information will be that of

ART Recherches et Technologies Avanc�es annonce une convention de restructuration et une proposition � ses cr�anciers

Fri, 20 Nov 2009 19:57:00 EST

MONTREAL, CANADA--(Marketwire - 20 nov. 2009) - ART Recherches et Technologies Avanc�es Inc. ("ART") (TSX:ARA), entreprise canadienne d'appareils m�dicaux et chef de file en d�veloppement de produits d'imagerie optique mol�culaire destin�s aux industries des soins de la sant� et pharmaceutique, annonce qu'� l'issue de son processus d'examen strat�gique, elle a conclu une convention avec Dorsky Worldwide Corp. ("Dorsky") afin de restructurer son bilan et son capital-actions et d'�tre en mesure de poursuivre ses activit�s.

ART Advanced Research Technologies Inc. Announces Restructuring Agreement and Proposal to Creditors

Fri, 20 Nov 2009 19:56:00 EST

MONTREAL, CANADA--(Marketwire - Nov. 20, 2009) - ART Advanced Research Technologies Inc. (ART) (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that its strategic review process has culminated in ART entering into an agreement today with Dorsky Worldwide Corp. ("Dorsky") to restructure ART's balance sheet and share capital and position it to continue in business. The agreement contemplates that ART will file a proposal (the "Proposal") to its unsecured creditors (the "Unsecured Creditors") under the Bankruptcy and Insolvency Act ("BIA") through KPMG Inc. (the "Trustee"). The meeting at which the Unsecured Creditors will vote on the Proposal is expected to be held on December 7, 2009 (the "Meeting"). The Proposal will provide, among other things, for the distribution of $375,000 to ART's Unsecured Creditors.

Polo Biology Global Group Corporation Board Appointments

Fri, 20 Nov 2009 16:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 20, 2009) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Polo Biology Global Group Corporation ("Polo" or the "Company") (TSX VENTURE:PGG) today announced the appointment of Dr. Jeff Zheng and Mr. John Morita as new independent directors of the Company. Both Dr. Zheng and Mr. Morita have also been appointed as independent members of the Company's Audit, Compensation, and Corporate Governance and Nominating Committees.

New Strategy to Improve Cognition in Down Syndrome Discovered by DSRTF Grant Recipients

Fri, 20 Nov 2009 15:49:00 EST

PALO ALTO, CA--(Marketwire - November 20, 2009) - The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine. The study explored contextual learning, and discovered that specific drug compounds can restore this important aspect of learning and memory in a mouse model, indicating a new potential therapeutic strategy to improve contextual learning for individuals with Down syndrome.

Annual and Special Shareholders meeting of ZoomMed inc./Pharmaceutical Contracts Signed for $1,482,500 During Q1-Q2

Fri, 20 Nov 2009 11:01:00 EST

Official launch of e-Pic communication network and update of activities

Assembl�e annuelle et extraordinaire de ZoomMed inc./Contrats pharmaceutiques sign�s totalisant 1 482 500 $ pour Q1-Q2

Fri, 20 Nov 2009 11:01:00 EST

Lancement officiel du r�seau e-Pic et mise � jour des activit�s

RECORDATI : EMEA/CHMP ADOPTS A POSITIVE OPINION FOR SILODOSIN (BRANDS UROREC(R) AND SILODYX(R))

Fri, 20 Nov 2009 10:09:00 EST

MILAN, ITALY--(Marketwire - November 20, 2009) - Recordati announces that on 19 November 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a Marketing Authorization for the medicinal products Urorec� and Silodyx� 4 mg, 8 mg, hard capsules, intended for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). The European Commission Decision is normally issued within 67 days from adoption of the CHMP Opinion.

SaBTO recommande l'utilisation du filtre � prions P-Capt(MD) afin d'assurer la protection des enfants contre la transmission de la vMCJ

Fri, 20 Nov 2009 09:26:00 EST

MONTREAL, QUEBEC, CANADA et LILLE, FRANCE--(Marketwire - 20 nov. 2009) - ProMetic Sciences de la Vie inc. (TSX:PLI) ("ProMetic") et MacoPharma SA ("MacoPharma") annoncent aujourd'hui que "l'Advisory Committee on the Safety of Blood, Tissues and Organs" "SaBTO", un comit� ind�pendant qui agit comme conseiller aupr�s du Minist�re de la sant� du Royaume-Uni, a recommand� l'utilisation du filtre � prions P-Capt(MD) pour pr�traiter les globules rouges provenant de dons de sang destin�s patients n�s apr�s le 1e janvier 1996. Le filtre, "nettoie" le sang en �liminant les prions causant la variante de la maladie de Creutzfeldt-Jakob ("vMCJ"). Le comit� a aussi indiqu� qu'il pr�voit, dans le futur, appuyer l'adoption � grande �chelle afin de traiter les 1,8 millions d'unit�s sanguines collect�s annuellement en Angleterre.

SaBTO Recommends Use of P-Capt(R) Prion Reduction Filter to Protect Children From vCJD Blood Transmission

Fri, 20 Nov 2009 09:15:00 EST

MONTREAL, QUEBEC, CANADA and LILLE, FRANCE--(Marketwire - Nov. 20, 2009) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") and MacoPharma SA ("MacoPharma") announce that the Advisory Committee on the Safety of Blood, Tissues and Organs ("SaBTO"), an independent Committee that advises the UK Department of Health ("DoH"), has recommended the adoption of the P-Capt(R) prion reduction filter to pre-treat red blood cells destined for children born since 1 January 1996. The filter, which 'cleans' blood prior to use, removes the prion responsible for variant Creutzfeldt-Jakob disease ("vCJD"). The Committee also indicated that the requirement for prion filtration should be reviewed in the event that further data on vCJD prevalence or filter efficacy becomes available.

GLG Life Tech Corporation Commences Trading on NASDAQ

Fri, 20 Nov 2009 09:15:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 20, 2009) - GLG Life Tech Corporation (TSX:GLG)(NASDAQ:GLGL) ("GLG" or the "Company"), the vertically integrated leader in the agricultural and industrial development of high quality stevia extracts, announced today that it has commenced trading on the NASDAQ Global Market under the symbol "GLGL". GLG's common shares are dual listed on the Toronto Stock Exchange and the NASDAQ Global Market.

Stem Cell Therapeutics Corp. Announces Positive Review by Data Safety and Monitoring Board for the Phase IIb Stroke Trial

Fri, 20 Nov 2009 08:30:00 EST

Independent Committee approves progress of Phase IIb clinical stroke trial

OPTIMIZERx Engages Beringea LLC as Advising Partner for Growth

Fri, 20 Nov 2009 08:00:00 EST

ROCHESTER, MI--(Marketwire - November 20, 2009) - OPTIMIZERx Corporation (OTCBB: OPRX) has engaged Beringea LLC, an investment banking and private equity firm, to assist in financial planning and strategic positioning for the company's continued growth.

"Beringea specializes in advising clients who are seeking to execute strategic transactions or find private financing," said David Lester, CEO, OPRIMIZERx. "As we continue to position OPTIMIZERx's growth within the healthcare marketplace we look to Beringea to be a strategic advisory partner for both growth and financial stability."

Scientists Discover, Patent, Sell 'Revolutionary' New Water-Treatment Technology at Sam Houston State University

Thu, 19 Nov 2009 17:06:00 EST

HUNTSVILLE, TX--(Marketwire - November 19, 2009) - Sam Houston State University has been awarded three federal patents to protect the technology and engineering associated with a "revolutionary" wastewater treatment system.

The university has applied for three additional patents and formed a company to manufacture, market and sell the systems. Its first customer is the United States Army.

The system is designed around a proprietary consortium of bacteria that have the capability to clean wastewater quickly with a high degree of efficiency and leave no toxic by-products.

LA County Helps Smokers Quit With Free Nicotine Patches and Gum

Thu, 19 Nov 2009 14:16:00 EST

Residents Are Encouraged to Take Advantage of Free Nicotine Patches and Gum During the Great American Smokeout

BASi Announces Compliance With NASDAQ Capital Markets Requirements

Thu, 19 Nov 2009 12:00:00 EST

WEST LAFAYETTE, IN--(Marketwire - November 19, 2009) - Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today that its application to transfer from the NASDAQ Stock Market to the NASDAQ Capital Market has been accepted. The transfer will occur on November 20, 2009.

The Company had previously been informed by the NASDAQ Stock Market that it did not meet minimum market value of publicly held shares and minimum bid price per share requirements. As a result of an increase in the market value of its stock, and lower minimum market value of publicly held shares for the Capital Market, the Company is now in compliance with the Capital Market requirements.

Evogene Reports Third Quarter 2009 Financial Results

Thu, 19 Nov 2009 11:56:00 EST

Revenues Increase to $2.6 Million for 3rd Quarter 2009, Compared to $0.9 Million in 2008 and Increase to $7.4 Million for First Three Quarters 2009, Compared to $1.1 Million in 2008

Interface Masters Technologies Announces a Unique Quad Segment 10 Gigabit Intelligent Bypass Switch Supporting 8 Aggregation TAP Ports

Thu, 19 Nov 2009 10:22:00 EST

Niagara 2818 Is a Unique Quad Segment 10GE Intelligent Bypass Supporting Failover, Uninterrupted Network Connectivity and Advanced Management of 10 Gigabit Inline Appliances

Unilife Appoints Unifill(TM) Automated Assembly Line Supplier

Thu, 19 Nov 2009 09:12:00 EST

Successful Product Assembly During Proof-of-Principle Activities

OmniComm Systems Continues Its Rapid Expansion by Opening a New Office in Monmouth Junction, NJ

Thu, 19 Nov 2009 09:00:00 EST

FORT LAUDERDALE, FL--(Marketwire - November 19, 2009) - OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC and eClinical marketplace, announced today that it has opened a new office in Monmouth Junction, NJ. The new location, situated equal distance between Princeton and Rutgers Universities, was chosen in part for its proximity to the Route One technology and pharmaceutical research corridor.

Facet Biotech Announces Four Presentations at American Society of Hematology Annual Meeting

Thu, 19 Nov 2009 08:30:00 EST

Elotuzumab Phase 1 / 2 Study Results Accepted for Oral Presentation

USAISR Researcher Dr. Andriy Batchinsky Identifies Vicor's PD2i(R) Nonlinear Algorithm as Most Promising Diagnostic for In-Field Trauma Triage in Presentation at the American Heart Association's Resuscitation Science Symposium 2009

Thu, 19 Nov 2009 08:30:00 EST

BOCA RATON, FL--(Marketwire - November 19, 2009) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), identified Vicor's proprietary PD2i� nonlinear algorithm and software as the most promising diagnostic for in-field trauma triage during a presentation before several hundred attendees at the American Heart Association's Resuscitation Science Symposium 2009 on November 14, 2009 in Orlando, Florida. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i� nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

COLD-FX(R) Maker Broadens Its Scientific Direction: Launches Pilot Trial of New Formulation LIP-01 Geared to Lowering Cholesterol and Lipids

Thu, 19 Nov 2009 08:00:00 EST

EDMONTON, ALBERTA--(Marketwire - Nov. 19, 2009) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) maker of COLD-FX today announced the launch of a pilot clinical trial of a new formulation, LIP-01 that has shown promise in reducing blood lipids - including cholesterol. Cholesterol can stick to the walls of arteries, causing atherosclerosis or "hardening of the arteries." This, in turn, can ultimately lead to a heart attack or stroke. In fact, more than one in three Canadians will be diagnosed with a heart disease at one point in their life.

American Diabetes Association Launches New Diabetes.org, Building a Community of Help, Hope and Support

Thu, 19 Nov 2009 08:00:00 EST

ALEXANDRIA, VA--(Marketwire - November 19, 2009) - To meet the changing needs of people affected by this growing epidemic, the American Diabetes Association has launched a completely redesigned www.diabetes.org in English and Spanish. Even though diabetes is a growing epidemic, a recent survey conducted by the Association showed that Americans received a failing grade in diabetes awareness. The web site's reorganization better targets audience members based on where their interest in diabetes lies (prevention, management, complications, caring for a loved one, etc.), and provides an engaging community with customizable tools and support, in addition to the research-based information that always has brought people to www.diabetes.org.

AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference

Thu, 19 Nov 2009 08:00:00 EST

BOTHELL, WA--(Marketwire - November 19, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced presentations on the company's exon skipping therapy for Duchenne muscular dystrophy at the TREAT-NMD / NIH International Conference taking place Nov. 17-19 in Brussels, Belgium.

At the conference, data from the company's clinical and preclinical programs were presented. An update on the company's ongoing systemic Phase 1b/2 trial of AVI-4658 was provided by Professor Francesco Muntoni, of the MDEX consortium in the UK, during an oral presentation and also summarized in a poster presentation. The most recent data from the ongoing Phase 1b/2 trial at two MDEX sites in the UK demonstrate that AVI-4658 was well tolerated by DMD patients in a dose escalation study that is now up to the sixth and final cohort (20 mg/kg). The maximum cumulative dose administered to date is 3132 mg and the ma

Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 Presented at the 2009 AACR-NCI-EORTC International Conference

Thu, 19 Nov 2009 07:30:00 EST

Data Support Hypothesis That GSK-923295 May Be Active in Combination With Other Chemotherapeutics in the Clinical Setting

Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy

Thu, 19 Nov 2009 06:45:00 EST

BERKELEY, CA--(Marketwire - November 19, 2009) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment. Dynavax expects to report top-line data from this trial in the second half of 2010. DV-601 is the first hepatitis B therapy to combine both the surface and core HBV antigens, and Dynavax has retained all commercial rights to this product.

Reflect Scientific Enters Cooperative Agreement With Resonon

Thu, 19 Nov 2009 06:18:00 EST

OREM, UT--(Marketwire - November 19, 2009) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, medical, industrial and transportation industries, announced the Company has entered into a collaborative arrangement with Resonon for incorporation of its unique hyper-spectral imaging technology into Reflect Scientific's industrial machine vision line of business.

Positive Final Lupuzor Trial Results

Thu, 19 Nov 2009 02:06:00 EST

LONDON--(Marketwire - November 19, 2009) -


Conference Call

ImmuPharma will host a conference call for analysts and investors
to discuss this announcement at 15:45 GMT  / 10:45 EST /  07:45
PST today. The dial-in details are: +44 (0)20 8609 1435 or US toll
free: 1 866 793 4279, participant PIN code 311368#.

FOR IMMEDIATE RELEASE                          19 NOVEMBER 2009


                           ImmuPharma PLC
                           ("ImmuPharma")

       ENCOURAGING FINAL PHASE IIb RESULTS SEEN WITH LUPUZORT
                 IN SYSTEMIC LUPUS ERYTHEMATOSUS

      ~ Greatest benefits seen in patients with moderate to severe
                   Systemic Lupus Erythematosus ~

ImmuPharma PLC (LSE: IMM) the specialist discovery and development
pharmaceutical company is pleased to announce today the final results
from a Phase IIb trial of LUPUZORT in active patients with Systemic
Lupus Erythematosus (

Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference

Thu, 19 Nov 2009 01:22:00 EST

BASEL, SWITZERLAND--(Marketwire - November 19, 2009) - Basilea Pharmaceutica Ltd. (SWISS: BSLN) presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference on Molecular Targets and Cancer Therapeutics in Boston (MA). BAL27862 is a novel, intravenous and orally bioavailable small molecule. It disrupts the microtubule network, a well established intracellular target in oncology, through a unique mechanism of action. The new data suggest that BAL27862 has the potential for a distinct anticancer profile in a wide range of cancer types, including those resistant to current treatment options.

TowerJazz and Tanner EDA Announce Process Design Kit (PDK) Collaboration for Power Management Device Design

Thu, 19 Nov 2009 01:00:00 EST

New PDKs Catalyst for Analog/Mixed-Signal Design Innovation

ZoomMed annonce le d�p�t sur SEDAR d'une circulaire de sollicitation de procurations modifi�es

Wed, 18 Nov 2009 17:20:00 EST

MONTREAL, QUEBEC--(Marketwire - 18 nov. 2009) - ZoomMed Inc. (TSX CROISSANCE:ZMD) annonce le d�p�t aujourd'hui sur SEDAR d'une circulaire de sollicitations de procurations modifi�e en date du 18 novembre 2009. Les modifications apport�es r�sultent d'une correspondance re�ue de l'Autorit� des march�s financiers du Qu�bec dans le cadre de son programme d'examen de l'information continue et visent � assurer la conformit� avec les exigences du R�glement 51-102A6 de la Loi sur les valeurs mobili�res.

ZoomMed Announces the Filing on SEDAR of an Amended Management Proxy Circular

Wed, 18 Nov 2009 17:19:00 EST

MONTREAL, QUEBEC--(Marketwire - Nov. 18, 2009) - ZoomMed Inc. (TSX VENTURE:ZMD) announces the filing today on SEDAR of an amended management proxy circular dated November 18, 2009. The amendment made to the document are the result of a correspondence received from the Autorite des marches financiers du Quebec in the framework of its review of continuous disclosure program, and were made to ensure the compliance with the requirements of Regulation 51-102F6 of the Securities Act (Quebec). The document which is the object of amendment is the management proxy circular dated October 19, 2009 for the shareholders meeting of ZoomMed to be held November 20, 2009.

Trend Exploration in Discussions to Acquire Preferred Distribution, Inc.

Wed, 18 Nov 2009 16:15:00 EST

ATLANTA, GA--(Marketwire - November 18, 2009) - Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) announces that it has entered advanced acquisitions discussions with Preferred Distribution, Inc., a distributor of medical, dental and healthy & beauty products ("Preferred").

Preferred is a revenue generating company that management feels can be grown aggressively with an increased sales and marketing effort. Preferred's dental products division is marketed through its website, www.preferreddist.com.

HearAtLast Announces Harbinger Research Report

Wed, 18 Nov 2009 16:14:00 EST

MISSISSAUGA, ON--(Marketwire - November 18, 2009) - (PINKSHEETS: HRAL) HearAtLast Holdings, Inc., a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced today that Harbinger Research has issued an Investment Report on the Company.

The research report provides a summary of the Company as an investment opportunity and overview of its business, its sales and marketing strategy and a discussion of the company's industry. It also includes the Company's projections of future results. To read the report please visit: http://www.harbingerresearch.com/link/13/237/HRAL

Thallion Presents Poster on the Apoptotic Properties of TLN-4601 at the AACR-NCI-EORTC Conference

Wed, 18 Nov 2009 16:06:00 EST

MONTREAL, QUEBEC--(Marketwire - Nov. 18, 2009) - Thallion Pharmaceuticals Inc. (TSX:TLN) today presented non-clinical data on TLN-4601, a proprietary small molecule with the potential to treat multiple tumor types, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. The data were exhibited in a poster presentation, titled TLN-4601 is a Novel Tumor Selective Pro-Apoptotic Agent Acting Independently of Bax, Bak or Bcl-2 Expression. "These results highlight the ability of TLN-4601 to rapidly induce cell death in a hematologic tumor cell line and expand our understanding of TLN-4601 beyond its inhibition of the Ras MAPK signaling pathway," said Lloyd M. Segal, Chief Executive Officer of Thallion. "Apoptotic pathways are validated molecular targets for new cancer therapeutics as apoptotic defects are commonly present in cancer cells. In this study, the differential sensitivity to TLN-4601 observed between a liquid tumor cell line and normal human blood lymphocytes

Thallion pr�sente un poster sur les propri�t�s pro-apoptotiques de TLN-4601 dans le cadre de la conf�rence de l'AACR-NCI-EORTC

Wed, 18 Nov 2009 16:06:00 EST

MONTREAL, QUEBEC--(Marketwire - 18 nov. 2009) - Thallion Pharmaceutiques Inc. (TSX:TLN) a annonc� aujourd'hui qu'elle avait pr�sent� des donn�es pr�cliniques portant sur TLN-4601, dans le cadre de la conf�rence Molecular Targets and Cancer Therapeutics de l'AACR-NCI-EORTC. Cette petite mol�cule, unique � la Soci�t�, a d�montr� un potentiel � traiter plusieurs types de tumeurs solides. Les donn�es ont �t� pr�sent�es sous la forme d'un poster, intitul� : TLN-4601 is a Novel Tumor Selective Pro-Apoptotic Agent Acting Independently of Bax, Bak or Bcl-2 Expression.

BASi Announces John B. Landis, Ph.D. Elected to Board

Wed, 18 Nov 2009 16:05:00 EST

WEST LAFAYETTE, IN--(Marketwire - November 18, 2009) - Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today that John B. Landis, Ph.D. has been elected to the Board of Directors of the Company.

Dr. Landis retired from his position as Senior Vice President, Pharmaceutical Sciences of Schering-Plough in October 2008 and is currently an Adjunct Professor at Purdue University's Department of Chemistry. Prior to joining Schering-Plough in 2003, Dr. Landis served in various management positions with Pharmacia Corporation and The Upjohn Company, including Director of Quality Control, Executive Director of Quality Control, Vice President of Quality Control, Vice President of Analytical Research, Vice President of CNS Psychiatry, and Senior Vice President of Preclinical Development.

BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates

Wed, 18 Nov 2009 16:02:00 EST

TORONTO, ONTARIO--(Marketwire - Nov. 18, 2009) - Bio-Extraction Inc. (TSX VENTURE:BXI) ("BioExx" or "the Company") is pleased to announce that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx^TMand Vitalexx^TM, as self-affirmed GRAS ("Generally Regarded as Safe") for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. GRAS is a food safety standard, set and administered in accordance with the regulations of the United States Food and Drug Administration ("FDA") which governs the use of additives, such as the BioExx protein products, in foods and beverages.

ExL Pharma's Leading European Digital Marketing and Public Relations Conferences to Be Hosted at Bayer Schering Pharma Corporate Headquarters, March 29-30th, 2010

Wed, 18 Nov 2009 15:30:00 EST

NEW YORK, NY--(Marketwire - November 18, 2009) - Bayer Schering Pharma and ExL Pharma today announced that the 2nd Annual Digital Pharma Europe and 2nd Annual European Public Relations and Communications Summit will be hosted at the Bayer Schering Pharma World Headquarters in Berlin, Germany on March 29-30, 2010.

These events which feature 50+ executive-level speakers from top industry leaders provide comprehensive presentations, panel discussions and opportunities for dialogue on issues that are most relevant to social media, web 2.0 technologies, product communications and corporate communications. 300+ executives are expected to attend from leading pharmaceutical, biotechnology and medical device organizations worldwide.

Total Facility Solutions Opens Raleigh Office to Support Regional Life Sciences and Renewable Energy Growth Opportunities

Wed, 18 Nov 2009 14:37:00 EST

RALEIGH, NC--(Marketwire - November 18, 2009) - Total Facility Solutions, Inc. (TFS), a specialty contractor and services company focused on critical process manufacturing infrastructure, announced today the opening of a Raleigh, NC office. The 6,400 square foot office, located in the Brier Creek area, will be the focal point for the company's life sciences facilities contracting service division and will also act as the company's regional hub to support its existing renewable energy and technology business throughout the southeast region of the United States.

(PINKSHEETS: KKUR) on the Front Line of Cancer Detection

Wed, 18 Nov 2009 13:34:00 EST

NOTE TO EDITOR: The Following Is an Investment Opinion Issued by the IO News Wire

Sunesis Reports Data From Nonclinical Studies of Voreloxin at AACR-EORTC-NCI Conference

Wed, 18 Nov 2009 12:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwire - November 18, 2009) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA from November 15-19, 2009.

In one study, clinical proof-of-mechanism is established in samples from patients treated with voreloxin in the Company's ongoing Phase 2 clinical study of voreloxin in combination with cytarabine in relapsed or refractory acute myeloid leukemia (AML). In an additional study, voreloxin's synergistic and additive effects are demonstrated in combination with cytarabine, azacitidine, decitabine and clofarabine, agents which are currently used in the treatment of AML. Results from both of these studies support the current combination study and identify potential opportunities for further clinical evaluation.

ABLYNX ACHIEVES THIRD MILESTONE IN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION

Wed, 18 Nov 2009 12:17:00 EST

GHENT, BELGIUM--(Marketwire - November 18, 2009) -

GHENT, Belgium, 18 November 2009 - Ablynx [Euronext Brussels: ABLX], announced today that it will receive an undisclosed milestone payment from Novartis. The payment has been triggered by successful delivery to Novartis of Nanobody� candidates which met specific criteria. This will be the third milestone payment that Ablynx has received from Novartis since the initiation of the alliance between the companies.

Novartis and Ablynx entered into the alliance in December 2005 to discover and develop therapeutic Nanobodies against targets that are difficult to address with conventional antibodies and fragments. Under the terms of this ongoing agreement, Ablynx receives upfront fees, license fees and funding for research and development. In addition, Ablynx is eligible for milestone payments and royalties upon commercialisation. Novartis has exclusive rights to develop and commercialise the Na

Ziva Abraham Joins Sensitel's Team of Resident Experts

Wed, 18 Nov 2009 11:00:00 EST

Leading Pharmaceutical Consultant Brings Bio-Pharma Industry Expertise to VeriSupply.com Subscribers

Linkage Biosciences Unveils LinkSeq(TM) -- a Revolutionary New Tool for Immunogenetic Testing

Wed, 18 Nov 2009 11:00:00 EST

Accurate, Easy and Faster Than Other HLA Testing Methods

Forensic Scientists Seek Answers, Solutions at Sam Houston State University Facility

Wed, 18 Nov 2009 10:12:00 EST

HUNTSVILLE, TX--(Marketwire - November 18, 2009) - After sheriff's deputies discovered human bones scattered around private property in Houston County recently, they turned to the Southeast Texas Applied Forensic Science Facility for help.

Joan Bytheway, a forensic anthropologist and director of the facility, along with volunteers from Sam Houston State University helped officers search for and recover the remains.

Death is a daunting topic for most people, but for Bytheway, her fellow scientists, investigators and students, it is the topic they live and breathe everyday.

ThermaFreeze Announces Formation of Majority-Owned Subsidiary American Diversified Medical Corporation

Wed, 18 Nov 2009 10:00:00 EST

ThermaFreeze to Offer ThermaTherapeutics Product Line Through ADM's Distribution Network

S3 Investment Company Comments on Status of Quarterly Financial Report

Wed, 18 Nov 2009 09:42:00 EST

DANVILLE, CA--(Marketwire - November 18, 2009) - S3 Investment Company, Inc. (PINKSHEETS: SIVC) today commented on the status of its consolidated financial report for the period ended September 30, 2009, which were scheduled to be posted to the Pink Sheets OTC Disclosure and News Service this week. Due to the turnover in the company's accounting personnel, the quarterly financials will be delayed approximately 30 days and are expected to be filed by December 15, 2009.

Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential

Wed, 18 Nov 2009 09:28:00 EST

BUFFALO, NY--(Marketwire - November 18, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a breakthrough discovery into the mechanism of action of the Company's first generation Curaxin anticancer compounds was published in an international health science journal, Cell Cycle (Neznanov et al., Cell Cycle 8:23, 1-11; December 1, 2009).

The published study examined the ability of the Company's prototype Curaxin (CBLC102, or quinacrine) to inhibit heat shock response, a major adaptive pro-survival pathway that rescues cells from stressful conditions involving accumulation of misfolded proteins (known as proteotoxic stress). Tumor cells typically become dependent on constitutive activity of this salvaging mechanism making them selectively susceptible to its inhibitors, especially if applied in combination with certain cancer therapies provoking proteotoxic stress.

Aldagen Announces Clinical Data for ALD-201 for Ischemic Heart Failure Presented at AHA

Wed, 18 Nov 2009 09:00:00 EST

DURHAM, NC--(Marketwire - November 18, 2009) - Aldagen, Inc. today announced that results from a Phase 1 clinical trial of ALD-201, a cell therapy being developed as a treatment for ischemic heart failure, were presented at AHA. In the study, ALD-201 was found to be well-tolerated and to improve myocardial perfusion. The data were presented at the American Heart Association Scientific Sessions 2009 by Emerson C. Perin, MD, PhD, FACC, Director, Clinical Research for Cardiovascular Medicine, and Medical Director, Stem Cell Center, Texas Heart Institute in an oral session.

State Representatives Dwayne Bohac and John Zerwas Recognize Two Local Doctors at MD Anderson to Bring Attention to Lung Cancer Awareness Month in Texas

Wed, 18 Nov 2009 09:00:00 EST

HOUSTON, TX--(Marketwire - November 18, 2009) - As part of an effort to increase awareness of lung cancer and its devastating effects on this state, State Representative Dwayne Bohac (R-Houston) and Dr. John Zerwas (R-Katy) honored the efforts of two local doctors who are battling on the front lines to treat the second leading killer of Americans. Lung cancer is one of the most common and deadly forms of this disease and will kill more people this year than all other cancers combined.

Intralinks Survey: Life Sciences Deal Activity Will Increase in 2010

Wed, 18 Nov 2009 09:00:00 EST

More Than Half of Industry Executives Anticipate Multiple Deals Next Year

Harte-Hanks and MedImmune Win Medical Marketing & Media Gold Award

Wed, 18 Nov 2009 08:45:00 EST

Pair Wins High Honor in "Best Use of Direct Marketing to Healthcare Professionals" Category for FluMist Campaign

Cardioxyl Pharmaceuticals Announces Pre-Clinical Results on Lead Clinical Candidate, CXL-1020 at American Heart Association Scientific Sessions 2009

Wed, 18 Nov 2009 08:30:00 EST

Pre-Clinical Studies Demonstrate Physiological Activity of CXL-1020

CTD Holdings, Inc. Announces Profitable 3rd Quarter Results

Wed, 18 Nov 2009 08:00:00 EST

HIGH SPRINGS, FL--(Marketwire - November 18, 2009) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today its third quarter results of operations.

CTD Holdings posted net income for the third quarter of $32,735 and reduced its total nine month loss to ($34,871) vs. ($74,606) in 2008, a 53.3% improvement. Revenue increased 51.5% for the three months ended September 30, 2009 vs. the September 30, 2008 period. Overall revenue for the nine months ended September 30, 2009 increased 24% to $460,277 vs. $371,230 for the comparable 2008 period. Working capital increased 21.4% to $539,000 as of September 30, 2009. Working capital is 88.4% of the company's total 2009 projected sales as of September 30, 2009.

AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day

Wed, 18 Nov 2009 08:00:00 EST

BOTHELL, WA--(Marketwire - November 18, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming Transformational Medical Technologies Initiative (TMTI) Industry Day taking place in Dallas, Texas.

Dr. Iversen will present on Thursday, Nov. 19, as part of a "Performers Panel" in which a panel of current TMTI performers from academia, biotechnology companies and large pharmaceutical firms will provide their perspectives on lessons learned from their experiences, timeframes and what was required in order to effectively do business with the TMTI.

Arrayit Technology Purchased by Johns Hopkins University to Study Rheumatoid Arthritis

Wed, 18 Nov 2009 07:00:00 EST

Medical Center Uses Arrayit Protein Microarray Platform to Identify Biomarkers for Autoimmune Diseases

Is Power3 Medical (OTCBB: PWRM) the Next "Vermillion Dollar Baby?"

Wed, 18 Nov 2009 06:48:00 EST

LOS ANGELES, CA--(Marketwire - November 18, 2009) - BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products (OTCBB: PWRM), the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

Skyepharma PLC - Board Change

Wed, 18 Nov 2009 02:00:00 EST

LONDON--(Marketwire - November 18, 2009) -


SKYEPHARMA PLC - BOARD CHANGE - CHAIRMAN

LONDON, UK, 18 November, 2009 - SkyePharma PLC (LSE: SKP) regrets to
announce today that its Chairman, Jeremy Scudamore, has informed the
Board that he intends to step down from the Board at the end of 2009
for health reasons.

Frank Condella, Non-Executive Director and former CEO of
SkyePharma, has agreed to take over as Non-Executive Chairman with
effect from 1 January 2010.

Dr Ken Cunningham, CEO of SkyePharma, commented: "The Board thanks
Jeremy for his valuable contribution as Chairman of the Company since
October 2007 and wishes him a speedy and successful recovery.  We are
very fortunate that Frank Condella is able to take over from Jeremy as
Chairman of SkyePharma. Frank will bring a strong sense of continuity
to the position as well as a deep understanding of the business and we
all look forward to continuing to work with

Basilea's Toctino(R) receives marketing authorization in Canada

Wed, 18 Nov 2009 01:21:00 EST

BASEL, SWITZERLAND--(Marketwire - November 18, 2009) - Basilea Pharmaceutica Ltd. announces that Toctino� (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has obtained regulatory approval from Health Canada.

"We are delighted that Health Canada has approved the use of Toctino for patients with severe chronic hand eczema unresponsive to potent topical steroids. These patients have often suffered with this chronic debilitating condition for many years. Our rigorous, well designed clinical studies have clearly shown that Toctino has the potential to benefit a significant number of patients suffering from chronic hand eczema," said Dr. Anthony Man, CEO Basilea Pharmaceutica Ltd.

Broncus Reports Early EASE Trial Results for Airway Bypass With Exhale(R) Drug-Eluting Stents

Tue, 17 Nov 2009 18:41:00 EST

MOUNTAIN VIEW, CA--(Marketwire - November 17, 2009) - Broncus Technologies, Inc., a medical technology company focused on developing and commercializing innovative solutions for lung diseases, is announcing early results of the EASE (Exhale Airway Stents for Emphysema) Trial, the first ever, double-blinded, randomized, sham-controlled device study for patients with emphysema/COPD. The EASE Trial, which was designed to evaluate the safety and effectiveness of the Airway Bypass procedure with Exhale Drug-Eluting Stents, did not meet the 6 month co-primary endpoints of improving forced vital capacity (FVC) and modified Medical Research Council (mMRC) dyspnea score when compared to controls, though mMRC alone did show statistically significant improvement.

HearUSA Updates Shareholder Rights Plan

Tue, 17 Nov 2009 16:05:00 EST

WEST PALM BEACH, FL--(Marketwire - November 17, 2009) - HearUSA, Inc. (NYSE Amex: EAR), the recognized leader in hearing care for the nation's top managed care organizations through a nationwide network of more than 2,000 hearing care providers, has updated and extended its shareholder rights plan, which has been in effect since December 14, 1999.

The rights plan is designed to ensure that the Company's board of directors is able to take appropriate action to protect the interests of the Company and its stockholders. The plan would help the board to maximize stockholder value in the event of a change of control of the Company, and otherwise to resist actions that the board considers likely to injure the Company or its stockholders.

American Diabetes Association Convenes 3rd Annual Disparities Conference

Tue, 17 Nov 2009 15:29:00 EST

Community Leaders Share Promising Practices to Reduce Racial Disparities in Obesity and Type 2 Diabetes

70 Companies Confirmed to Present at OneMedForum 2010 Investment Conference

Tue, 17 Nov 2009 14:48:00 EST

OneMedPlace's Third Annual Finance Conference for Emerging Public and Private Healthcare Companies Will Be Held January 12-14 at San Francisco's Sir Francis Drake Hotel.

Growing Cross-Industry Demand for HPC and Cloud Computing Fuels Cycle Computing's Rapid Expansion

Tue, 17 Nov 2009 13:02:00 EST

Adds Industry-Leading Pharmaceutical and Life Sciences Companies to Client Roster

Mitrionics Awarded Funding From VINNOVA for Portable Parallel Programming Project

Tue, 17 Nov 2009 12:36:00 EST

LOS GATOS, CA--(Marketwire - November 17, 2009) - Mitrionics, Inc., the technology leader in FPGA-based hybrid computing, reports that VINNOVA, the Swedish governmental agency for innovation systems, today announced that it has awarded 3,826,000 SEK (approximately $555,000 USD) in funding for Mitrionics' Portable Parallel Programming project. This is within the framework of the Forska&Vax (Research&Grow) program that focuses on R&D in small and medium enterprises (SMEs). Mitrionics is currently demonstrating a proof-of-concept for the new portable parallel programming technology at the Supercomputing 2009 Conference in Portland, Oregon.

MethylGene pr�sente des donn�es de phase I favorables au sujet de l'action du MGCD265 sur des tumeurs solides � la conf�rence internationale AACR-NCI-EORTC

Tue, 17 Nov 2009 12:30:00 EST

Le compos� est bien tol�r� et pr�sente des signes d'activit� ainsi que des caract�ristiques pharmacodynamiques Trois �tudes cliniques sont en cours

MethylGene Reports Favorable Phase I Data for MGCD265 in Solid Tumors at the AACR-NCI-EORTC International Conference

Tue, 17 Nov 2009 12:30:00 EST

Compound is well tolerated with signs of activity and pharmacodynamic effect Three clinical trials ongoing

Acceleware and Kelman Technologies Deliver Accelerated Seismic Processing Using GPUs

Tue, 17 Nov 2009 12:25:00 EST

Kelman Increases Resolution and Drives Computational Efficiency with Acceleware

WesternU Gala Raises Money for Student Scholarships

Tue, 17 Nov 2009 12:01:00 EST

POMONA, CA--(Marketwire - November 17, 2009) - The casino tables were packed with guests cheering every lucky hand and roll of the dice, but students were the true winners at WesternU's annual fundraising gala "A Tribute to Caring" on Nov. 14, 2009.

A capacity crowd of 520 guests raised $130,000 for student scholarships and feted community leaders dedicated to higher education at Disney's Grand Californian Hotel in Anaheim.

WesternU President Philip Pumerantz, PhD, thanked everyone for attending ATC. The goal of the event is to support students as they become caring, compassionate health care providers.

American Health Care ("AHC"), Rocklin, California, Announces Plans to Implement Diabetes Management Program for the City of Charlotte; AHC's Disease Management Sites Now in 26 States

Tue, 17 Nov 2009 12:00:00 EST

CHARLOTTE, NC--(Marketwire - November 17, 2009) - American Health Care ("AHC") today announced that the City of Charlotte has selected American Health Care to manage its Diabetes Condition Management Program. Timothy D. Mayes, Human Resources Director for the City of Charlotte stated, "This is a critical step in the City's progressive commitment to improving the health of its employees and beneficiaries. Our decision to partner with American Health Care is based upon their unique data tracking and integration technology, extensive experience, and their proven track record of success in documented outcomes and peer reviewed data."

RevMed Locks in Acclaimed MRI Pioneer on Eve of National Product Debut

Tue, 17 Nov 2009 11:52:00 EST

President Tom O'Brien Signs 3-Year Employment Commitment

I-many to Host Health Care Reform Symposium

Tue, 17 Nov 2009 11:35:00 EST

Event to Explore Health Care Reform's Impact on the Pharmaceutical Industry

Model N and Sierra Atlantic Extend Software Development Partnership to Bring Leading Revenue Management Solutions to Indian Pharmaceutical Market

Tue, 17 Nov 2009 11:33:00 EST

Partnership Will Help Industry Profitably Respond to Burgeoning Demand in U.S. Market

Gregg A. Mosley, President of Biotest Laboratories of Minneapolis, MN, to Address Biological Counter-Terrorism Seminar on "Methods of Destruction for the Root Causes of Contamination by Dangerous Pathogens"

Tue, 17 Nov 2009 11:32:00 EST

MINNEAPOLIS, MN and NEW YORK, NY--(Marketwire - November 17, 2009) - Gregg Mosley, President of Biotest Laboratories of Minneapolis, MN (www.biotestlabs.com), a world-renowned expert in sterilization of medical products, will address the Biological Counter-Terrorism Seminar hosted by BioDefense Corporation, November 17, 2009 at the Waldorf Astoria Hotel, New York, NY.

According to host John Meyer, President of BioDefense Corporation (NYPD-Retired), "Bioterrorism is an ever-present threat to any entity, public or private. Potential perpetrators such as disgruntled employees and customers, business competitors, activists, extortionists, terrorists, and any others with ill intent will be described and discussed. Special focus will be on understanding how a bio-pathogen attack occurs and what procedures can be employed to mitigate infection and contamination."

Allon Chosen as "Top 10 Partnering Candidate" and Presenting at Major Partnership Conference

Tue, 17 Nov 2009 09:25:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 17, 2009) - Allon Therapeutics Inc. (TSX:NPC) announced today its lead drug candidate, davunetide, has been selected as one of the Top 10 partnership candidates by a leading industry expert.�The 2009 Windhover Therapeutic Areas Partnership Conference features the Top 10 candidates. Bruce Morimoto, Vice-President of Drug Development at Allon, will present an overview of the davunetide program at the conference in Boston, MA on November 18.

New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development

Tue, 17 Nov 2009 09:00:00 EST

BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as R&D funding for those diseases has increased, according to a recently completed study by the Tufts Center for the Study of Drug Development.

According to the study, the annual rate of new product approvals worldwide for neglected diseases increased from an average of 1.8 in 1975-99 to 2.6 in 2000-09.

OmniComm's TrialMaster(TM) EDC Solution Selected by Leading Medical Device Manufacturer for Phase IV Cardiovascular Device Study

Tue, 17 Nov 2009 09:00:00 EST

Long Term Customers Continue to Propel OmniComm's Fast-Paced Growth

Xceedium(R) Extends Its Award-Winning Access Control and Audit Capabilities to Mainframe and Virtualized Environments

Tue, 17 Nov 2009 08:36:00 EST

New Version of Xceedium GateKeeper Provides Comprehensive Support for Centralized Computing Models

RAE Systems Granted United States Patent for Radiation Detector Dosimeter

Tue, 17 Nov 2009 08:35:00 EST

Detector Deployed in GammaRAE II R Increases Measurement Range and Detects Rate and Dose

Bio-Solutions Corp. Announces a Mission to Africa to Perform a Pilot Trial of GreenEx(TM)

Tue, 17 Nov 2009 08:34:00 EST

MONTREAL, QUEBEC--(Marketwire - Nov. 17, 2009) - Bio-Solutions Corp. (OTCBB:BISU), announces a mission to perform a pilot trial for its main product GreenEx(TM) in a highly infested site within one of the targeted countries. In its growth framework and discussion with three African Countries, Bio-Solutions Corp. accomplishes a second and important step, i.e. a first pilot trial design to show on site efficiency of GreenEx(TM) in December, 2009. "We are proud to have the opportunity to show the effectiveness of our product so quickly after its regulatory approval by the health authorities of this West African country. Bio-Solutions Corp's Team will travel to the West African Country to evaluate the environmental condition in order to develop the perfect spreading strategy to assure the success of this experiment. This will be the final step prior to a commercial supply agreement," declares Dr Chaumillon.

Chembio Diagnostics to Present at the FDA Blood Products Advisory Committee on November 17, 2009

Tue, 17 Nov 2009 08:30:00 EST

Company to Present Features of Its DPP(R) HIV 1 & 2 Oral Fluid Screening Assay in Meeting to Discuss Over-the-Counter Home-Use HIV Test Kits

Green Planet Reports Third Quarter 2009 Results: Sales Up Over 60% From Previous Quarter

Tue, 17 Nov 2009 08:30:00 EST

Operating Income and Net Income at $1.5 Million and $1.1 Million Respectively, Show Substantial Gains From Previous Quarter and Same Period a Year Ago

ONE Holdings Announces Filing for NASDAQ Listing and Name Change

Tue, 17 Nov 2009 08:30:00 EST

ONE Also Launches New Site: www.onehcorp.com

Paragon Biomedical Executive Anticipates Surge of Collaborations in Clinical Research

Tue, 17 Nov 2009 08:04:00 EST

Attendees at Major European Conference Optimistic About Future Growth

Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are a Major Opportunity in Fighting Diabetes

Tue, 17 Nov 2009 08:00:00 EST

VANCOUVER, BC--(Marketwire - November 17, 2009) - Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity drug development, says the latest results from a clinical trial with a competitor's SGLT Inhibitor demonstrates the major opportunity for the company with its unique molecules.

Sirona Biochem CEO, Dr. Howard Verrico, said, "New data on dapagliflozin reported at the recent 20th World Diabetes Congress in Montreal shows SGLT2 inhibitor dapagliflozin lowered levels of HbA1c blood sugar significantly more than the placebo and that it was safe and well tolerated with no treatment-related serious adverse events (1). That is why SGLT inhibitors are deservedly attracting worldwide attention from major pharmaceutical companies around the world."

ViStra Growth Partners to Begin Accepting Clients

Tue, 17 Nov 2009 08:00:00 EST

HIGH SPRINGS, FL--(Marketwire - November 17, 2009) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today that ViStra Growth Partners, Inc., a wholly owned subsidiary of CTD Holdings, Inc., will begin accepting clients.

ViStra is a consulting company providing corporate planning and strategic growth strategies for private, start-up and micro-cap public companies. ViStra provides its clients with consulting services relating to business structure, organizational management, capital procurement, accessing public capital markets, strategic acquisitions and investor communications. ViStra intends to focus its full suite of services in support of clients' needs, which are primarily privately held corporations and start-ups. In addition, the company believes that it can deliver a complete solution of communication services to meet the needs of

The X PRIZE Foundation Announces First Asia-Based Contender for Genome Sequencing Prize

Tue, 17 Nov 2009 08:00:00 EST

Taiwanese Team, cracker, to Compete for the $10 Million Archon X PRIZE for Genomics

Adeona Pharmaceuticals Announces Third Quarter 2009 Results and Achievements

Tue, 17 Nov 2009 07:31:00 EST

Webcast Scheduled for 9:00 AM EST

Cytokinetics Presents Non-Clinical Data From Its Smooth Muscle Contractility Program at the 2009 Scientific Sessions of the American Heart Association

Tue, 17 Nov 2009 07:30:00 EST

Data Supports Hypothesis That Inhibition of Smooth Muscle Myosin May Represent a Novel Approach to Treat Patients With Systemic or Pulmonary Hypertension

Atrium Announces the Release of Interim Results From COBEST Clinical Study

Tue, 17 Nov 2009 07:00:00 EST

HUDSON, NH--(Marketwire - November 17, 2009) - Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. Prof. Patrice Mwipatayi of Royal Perth Hospital, Australia, presented interim data on the Covered versus Balloon Expandable Stent Trial known as COBEST at the 2009 VIVA (Vascular InterVentional Advances) meeting in Las Vegas. The presentation was part of the VIVA 2009 Late-Breaking Trials.

New Business Win: Callidus Software Signs New SaaS Customer for Monaco Suite

Tue, 17 Nov 2009 07:00:00 EST

SPM Market-Leader Demonstrates Strong Momentum in Pharma Industry

IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film

Tue, 17 Nov 2009 06:01:00 EST

SAINT LAURENT, QUEBEC--(Marketwire - Nov. 17, 2009) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.

Agennix AG Schedules Conference Call on November 23rd to Discuss Third Quarter 2009 Financial Results

Tue, 17 Nov 2009 04:58:00 EST

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - November 17, 2009) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that the Company will hold a conference call on Monday, November 23, 2009 at 3 PM CET/9 AM ET to discuss financial results for the third quarter of 2009 and provide a corporate update. The results will be published on November 23 in advance of the conference call.

CardioComm Solutions, Inc. Signs Software Development Agreement and Adds New Director

Mon, 16 Nov 2009 20:45:00 EST

VICTORIA, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2009) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (the "Company") today announced that it has signed a software development agreement with MD Primer Inc. ("MD Primer") under which MD Primer has retained the Company to develop a new software platform of the GlobalCardio ^TM, GEMS ^TM�and GEMS^TMadd-on modules and other pipeline software systems. As consideration for developing the software, the Company will receive aggregate payments of $500,000, payable in accordance with the milestone payment schedule set forth in the development agreement. MD Primer will also grant the Company a non-exclusive license to the software developed under the agreement, provided that the Company pays

Radient Pharmaceuticals Files Extension for Third Quarter 2009 Financial Results

Mon, 16 Nov 2009 20:37:00 EST

TUSTIN, CA--(Marketwire - November 16, 2009) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company, announced today it has filed a Notification of Late Filing under Rule 12b-25 of the Securities Exchange Act of 1934, as amended, with the Securities and Exchange Commission (the "SEC") for its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2009.

This filing provides for an extension for the filing of its Quarterly Report on Form 10-Q until November 23, 2009. The Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2009, could not be filed within the prescribed period because the Company was unable to compile certain information required in order to permit the Company to file a timely and accurate report on the Company's financial condition. This inability could not have been eliminated by the Company without unreasonable effort

This Week on ORLive (November 16, 2009): Join a Live Interactive Presentation of Liver Transplant Surgery, a Live VATS Technology and Techniques Panel With Leading Surgeons, and View a Live Hip Replacement Surgery

Mon, 16 Nov 2009 19:26:00 EST

ORLive -- Your Destination for Live and On-Demand Surgery Video

Healthcare Reform Can Be Painless

Mon, 16 Nov 2009 17:12:00 EST

Expert Reveals That Fixing FDA Can Save Consumers Hundreds of Billions of Dollars

Dragon Pharma Reports 2009 Third Quarter Financial Results

Mon, 16 Nov 2009 17:00:00 EST

Net Income Increased 108% to $2.20 Million for the Third Quarter

BioExx Announces Q3 2009 Results

Mon, 16 Nov 2009 16:43:00 EST

Conference Call: Tuesday, November 17, 10:00 a.m. ET Dial-in Numbers: 416-340-8061 / 866-225-0198

BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness in Clinical Study

Mon, 16 Nov 2009 16:10:00 EST

ActiPatch Proved 50 Percent More Effective Than Acetaminophen

Theratechnologies to Present at Lazard Capital Markets Conference

Mon, 16 Nov 2009 15:48:00 EST

MONTREAL, QUEBEC--(Marketwire - Nov. 16, 2009) - Theratechnologies (TSX:TH) announced today that Dr. Andrea Gilpin, Vice President, Investor Relations and Communications, will be presenting an overview of Theratechnologies at the 6th Annual Lazard Capital Markets Healthcare Conference, which will take place at The St. Regis, in New York City. At her presentation on Wednesday, November 18 at 11:30 a.m., Dr. Gilpin will review the operational accomplishments over the last year and discuss Theratechnologies' strategy and growth opportunities.

Pr�sentation de Theratechnologies � la conf�rence Lazard march�s des capitaux

Mon, 16 Nov 2009 15:48:00 EST

MONTREAL, QUEBEC--(Marketwire - 16 nov. 2009) - Theratechnologies (TSX:TH) annonce aujourd'hui que Mme Andrea Gilpin, vice-pr�sidente, relations avec les investisseurs et communications, pr�sentera un survol de la Soci�t� dans le cadre de la 6e �dition de la conf�rence portant sur les soins de sant� organis�e par Lazard march�s des capitaux, qui aura lieu au St. Regis, � New York. Pr�vue ce mercredi 18 novembre � 11 h 30, la pr�sentation de Mme Gilpin reviendra sur les accomplissements op�rationnels de la derni�re ann�e et s'attardera sur la strat�gie et les opportunit�s de croissance de Theratechnologies.

Impact Fusion International Develops Caffeine Free 2 Ounce Hangover Relief Drink

Mon, 16 Nov 2009 15:26:00 EST

Hangover Relief Beverage Developed to Combat $148 Billion in Lost Productivity in the United States

PBMI Issues Last Call for Entries in Drug Benefit Awards Program

Mon, 16 Nov 2009 14:11:00 EST

SCOTTSDALE, AZ--(Marketwire - November 16, 2009) - The Pharmacy Benefit Management Institute (PBMI) is accepting final entries in its annual drug benefit awards program. Deadline to submit for an Rx Benefit Innovation Award is Dec. 1, 2009.

Award winners will be honored at PBMI's 15th Anniversary Drug Benefit Conference to be held February 17-19 in Phoenix. The education and networking event draws human resource professionals, health plan executives, pharmacy directors, benefits consultants and pharmacy benefit managers from across the nation.

Advanced BioMedical Technologies Inc. Begins Phase II Animal Test on PA Miniscrews and Plates

Mon, 16 Nov 2009 13:05:00 EST

GUANGZHOU, CHINA and MIDDLETOWN, NY--(Marketwire - November 16, 2009) - Advanced BioMedical Technologies Inc. (OTCBB: ABMT) announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd. ("ABT-CHANGHUA"), has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

Ambrilia Biopharma d�pose son rapport sur la situation

Mon, 16 Nov 2009 10:13:00 EST

Attention directeurs des rubriques affaires/finance/sant�

Ambrilia Biopharma Provides Bi-Weekly Status Update

Mon, 16 Nov 2009 10:12:00 EST

Attention business/financial/health editors

Kane Biotech Announces Private Placement Offering

Mon, 16 Nov 2009 10:06:00 EST

WINNIPEG, MANITOBA--(Marketwire - Nov. 16, 2009) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the "Company"), today announces a non-brokered private placement offering (the "Offering") for gross proceeds of up to $500,000 consisting of up to 3,846,154 units ("Units") at a price of $0.13 per Unit. Each Unit will be comprised of one common share of the Company (a "Share") and one half of one Share purchase warrant (a "Warrant"). Each whole Warrant will expire 18 months from the date the Warrant is issued (the "Expiry Date") and will entitle the holder to purchase one Share at a price of $0.17 per Share if purchased within 6 months from the date the Warrant is issued or $0.25 per Share if purchased after 6 months up to the Expiry Date.

Xigen Announces $20 Million Series B Financing and Clinical Safety Data for Lead Product XG-102

Mon, 16 Nov 2009 09:37:00 EST

Safety of Highly Innovative Cell-Penetrating Peptide Technology Shown in Phase I Study; Validated Pipeline of Stabilized Peptides Efficient at Very Low Doses Opens New Opportunities for Inflammatory Diseases

BioPharm Insight and i3 Pharma Informatics Announce Clinical Information Alliance

Mon, 16 Nov 2009 09:32:00 EST

i3 Pharma Informatics to Contribute Prescription Claims and J Code Data, Deepening the Physician Profiles Provided by BioPharm Insight

REMINDER: This Week on ORLive (November 11, 2009): Seven New Live Programs Featuring a Trauma and Critical Care Symposium, Live Orthopaedic Surgeries, a Live Demonstration of Synthetic Sealant for European Audiences, and a Special Parent Focused Interactive Discussion on H1N1 and Children

Mon, 16 Nov 2009 09:15:00 EST

ORLive -- Your Destination for Live and On-Demand Surgery Video

ValiMed(TM) Launched in the Middle East by Virtus Trading LLC

Mon, 16 Nov 2009 09:05:00 EST

Major Presentations and Seminars by CDEX and Virtus to Health Officials Mark the Launch of ValiMed in the Middle East

Genome British Columbia: Genomics to Provide More Effective Treatment Options for Mining Wastewater

Mon, 16 Nov 2009 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2009) - Companies that are faced with the challenge of cleaning up toxic wastewater from mining operations will soon have more reliable bioremediation options. New research from Genome BC will harness the potential of microbes naturally present in mine bioremediation to help improve strategies for cleaning up contaminated mine sites. This method of bioremediation will provide a valuable alternative to some current mine effluent treatment methods that require large-scale employment of chemicals to treat water contaminated by metal leaching and acid rock drainage.

UC San Diego Radiologists Begin Patient Flow & Efficiency Study

Mon, 16 Nov 2009 09:00:00 EST

Innovative On-Cue(TM) Software From Allocade Builds on Hubble Space Telescope Experience

Phase 1/2 Results for Aldagen's ALD-301 Critical Limb Ischemia Clinical Study Presented at AHA

Mon, 16 Nov 2009 09:00:00 EST

DURHAM, NC--(Marketwire - November 16, 2009) - Aldagen, Inc. today announced that researchers presented results from its multicenter Phase 1/2 clinical trial of ALD-301, a cell therapy being developed as a treatment for advanced critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD). In the study, ALD-301 was well-tolerated, and patients in the treatment group were shown to have increased blood flow and improved clinical status. The data were presented at the American Heart Association Scientific Sessions 2009 by Emerson C. Perin, MD, PhD, FACC, Director, Clinical Research for Cardiovascular Medicine, and Medical Director, Stem Cell Center, Texas Heart Institute in a general poster session.

Ondine Announces Agreement to Acquire Advanced Photodynamic Technologies, Inc.

Mon, 16 Nov 2009 08:40:00 EST

VANCOUVER, BRITISH COLUMBIA and MINNEAPOLIS, MINNESOTA--(Marketwire - Nov. 16, 2009) -

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES

Ondine Biopharma Corporation (the "Company" or "Ondine") (TSX:OBP)(AIM:OBP) and Advanced Photodynamic Technologies, Inc. (APT) are pleased to announce that Ondine and the owners of APT have signed a binding definitive agreement pursuant to which Ondine will acquire APT in exchange for common shares of Ondine. APT is a privately-held leader in research and development of photodynamic drugs and devices for antimicrobial and oncotherapeutic applications. Closing of the acquisition is expected to occur on or about November 30^th, 2009 and is subject to certain conditions, including receipt of regulatory approvals and completion of due diligence to the satisfaction of Ondine.

Med BioGene Announces Proposed U.S. IPO, NASDAQ Listing and Interim Private Placement

Mon, 16 Nov 2009 08:30:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2009) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR TO UNITED STATES PERSONS OR FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES

Med BioGene Inc. (TSX VENTURE:MBI) today announced that it has engaged Rodman & Renshaw, LLC to act as lead underwriter in connection with MBI's proposed initial public offering of common shares in the United States (the "U.S. IPO") and concurrent listing of its common shares on The NASDAQ Capital Market. MBI intends to file as soon as possible with the United States Securities and Exchange Commission a registration statement in respect of the U.S. IPO. Listing of the common shares on The NASDAQ Capital Market will be subject to MBI fulfilling all applicable listing requirements.

Vicor Technologies Announces Filing of 10-Q on November 13, 2009

Mon, 16 Nov 2009 08:30:00 EST

Ends Quarter With Strongest Balance Sheet in Several Years

Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.

Mon, 16 Nov 2009 08:17:00 EST

TORONTO, ONTARIO--(Marketwire - Nov. 16, 2009) - Cannasat Therapeutics Inc. ("Cannasat") (TSX VENTURE:CTH) announced today that Anthony J. Giovinazzo has been appointed to succeed David Hill as Chief Executive Officer, and joins the Company as President and Chief Executive Officer. Mr. Giovinazzo is an executive with 16 years of international biopharmaceutical experience in drug development for treatment of central nervous system diseases (Central Nervous System "CNS"). Mr. Hill will continue with the company as Vice Chairman and will become an advisor to Mr. Giovinazzo.

DataDirect Networks Simplifies Storage Scale-Out by Serving File Systems Natively From Revolutionary Open Appliance Storage Systems

Mon, 16 Nov 2009 08:00:00 EST

DDN Open Storage Appliance SFA10000E, Utilizing Storage Fusion Architecture, Integrates Leading HPC File Systems Within the Storage Platform to Reduce Costs and Simplify Deployment

DataDirect Networks Simplifies Storage Scale-Out by Serving File Systems Natively From Revolutionary Open Appliance Storage System

Mon, 16 Nov 2009 08:00:00 EST

DDN Open Storage Appliance SFA10000E, Utilizing Storage Fusion Architecture, Integrates Leading HPC File Systems Within the Storage Platform to Reduce Costs and Simplify Deployment

Sunesis Reports Financial Results for the Third Quarter of 2009

Mon, 16 Nov 2009 08:00:00 EST

Voreloxin Abstracts Accepted for Presentation at ASH

Skystar Bio-Pharmaceutical Company Announces Third Quarter 2009 Financial Results

Mon, 16 Nov 2009 07:00:00 EST

Company Reports Record Quarterly Revenue of $12.78 Million and Adjusted Net Income of $4.25 Million; and Adjusted EPS of $0.61 per Share

CambridgeSoft Announces Investment by Health Evolution Partners and Goldman Sachs

Mon, 16 Nov 2009 06:00:00 EST

New Investment Allows Expanded Services to Life Sciences Market